· 2016-10-06 · Welcome to Drug Discovery 2016 As Scientific Program chairs it is our great pleasure to welcome you to Liverpool and the 10th Annual ELRIG Drug Discovery event. Through

www.elrig.org/drug-discovery-2016

#ELRIGDD16

Welcome to Drug Discovery 2016

As Scientific Program chairs it is our great pleasure to welcome you to Liverpool and the 10th Annual ELRIG Drug Discovery event.

Through the efforts of our volunteer organising committee, we have been able to assemble a top class line up of scientific speakers organised into 6 thematic tracks over 2 days. Some, like our Assay Development & Screening and Innovations in Chemistry sessions will be recognisable from years before. Others like the Cell & Gene Therapy track are new and reflect hot topics and trends in the Drug Discovery Field. With three plenary lectures, over 50 session speakers, 180 posters and a vibrant exhibition hall we are sure there will be something for all!

This year’s venue, the Liverpool Echo Arena is a fantastic place for us to meet. The state of the art conference facilities positioned close to one of the UKs most historic and eclectic city centres provide a perfect backdrop for the scientific and networking interactions upon which ELRIG is founded. The excellent travel links to Liverpool will hopefully see you arrive fresh and energised!

We would like to sincerely thank Liz Quinn for her immense contribution in shepherding ourselves and the Program Chairs through the organising process. Without her and the ELRIG back office and volunteers this meeting would not be possible. Without you, the meeting delegate, we have nothing too. We thank you in advance for your participation and look forward to connecting with you over the next couple of days. As always we welcome your feedback on how we can further improve the agenda to ensure the growth and success of ELRIG DD for the next decade. Have fun in Liverpool, and enjoy.

Rachel GrimleyChas Bountra Del Trezise

A message from the ELRIG chairman

On behalf of ELRIG I would like to welcome you to the 10th anniversary Drug Discovery meeting. Since the first meeting in 2006 the Drug Discovery meeting has gained an outstanding reputation for the presentation of breaking science, the opportunity to meet colleagues from across the field and for the quality of the poster sessions and vendor exhibition. This continues at the 2016 meeting in Liverpool with an outstanding scientific program created by Chas Bountra, Del Trezise and Rachel Grimley, accompanied by an exhibition with over 70 participating companies, alongside vendor workshops the Dragon’s Den, the Innovation Zone and of course the 10th Anniversary Celebration at the Museum of Liverpool.

Central to the mission of ELRIG is the delivery of high quality science, freely available to the community, to create networking opportunities to advance the science and technology of drug discovery. It is a defining feature of ELRIG that our meetings continue to be free to attend. This is only possible due to the volunteers who freely give their time, and of course to the companies who provide sponsorship through exhibition at our meetings all of whom have my deepest thanks.

The last year has seen considerable change within ELRIG with the creation of three workgroups tasked with developing future strategy for the organisation; these are the Science Strategy, Delegate Outreach and Exhibitor Outreach Workgroups led by Adrian Kinkaid, Fabrice Turlais and Kevin Moore respectively. To learn more about the activities of these groups please reach out to Adrian, Fabrice or Kevin. Looking ahead to 2017 these workgroups are developing strategies for the establishment of networking events in key science clusters across the UK and for the growth of ELRIG in Europe. If you have any feedback on how you would like ELRIG to develop please contact any member of the ELRIG General Committee.

During 2016 ELRIG will run five scientific meetings attracting a total attendance of around 2500 people. We have one further meeting in 2016, Pharmaceutical Flow Cytometry and Imaging at GSK Stevenage in November. Looking to 2017 we are delighted to announce that the Research and innovation meeting will be moving to Cambridge in March, that Cell Based Assays will be returning to Gothenburg in May, with Drug Discovery again in Liverpool in October and exciting plans In development for a new meeting in December.

At a personal level I was honoured to be elected Chair of ELRIG earlier this year. I would like to thank Sanj Kumar for his leadership of ELRIG over the last three years, and look forward to working with him in his new role as Sales Director. I would also like to thank my colleagues on the ELRIG Board and General Committee for their continued support to the organisation, and especially to Liz Quinn who has worked tirelessly in her role as Science Director. Last I would like to thank Tara Shanks and Rhona Bennett from the ELRIG office without whom these meetings would not happen.

Finally, I would like to thank all of you for joining us in Liverpool and hope to see you again at future ELRIG meetings.

Kind regards

Steve ReesELRIG Chair

Our Plenary Keynote Speakers

Drug safety issues remain a major cause of drug attrition during development, as well as soon after marketing. The potential of a new drug to cause adverse drug reactions may be picked up during preclinical development, which may lead to discontinuation of development. Alternatively, apparently non-dose dependent reactions may only manifest themselves during early phase clinical phase trials, or if rare, during post-marketing surveillance. Adverse reactions that are a direct

extension of the known pharmacology of the drug (so-called type A reactions) may be detectable in animal models, and development of more precise dosing protocols may overcome issues in man. By contrast, adverse reactions which are “idiosyncratic” (also termed type B) require the development better pre-clinical systems which are more predictive of effects in man. However, for most types of adverse reactions, it may not be possible to capture the individual susceptibility factor in pre-clinical test systems. Such reactions are often detected during post-marketing surveillance and require investigation and development of risk-minimisation measures after the drug has been approved.

With over 50% of current drugs directed at membrane receptors, new technologies are required to study these demanding targets. Native mass spectrometry, in which proteins retain their folded state and interactions, is an exciting advance. Recent breakthroughs allow this technology to be applied to membrane protein assemblies. Released directly into the gas phase from micelles, or lipid-based solubilisation vehicles, we can preserve non-covalent interactions allowing small molecules to

be observed directly attached to membrane receptors. In my lecture I will demonstrate how we can exploit these new mass spectrometry approaches to understand protein interactions in a number of membrane protein drug targets, from ion channels to G-protein coupled receptors. Beyond defining binding stoichiometry I will show how we can use the approach to assign affinity constants to multiple ligands simultaneously. I will also show how we are deciphering the importance of post-translational modifications and the surrounding lipid bilayer using new methodologies developed in our laboratory.

Professor Munir PirmohamedDavid Weatherall Chair in Medicine, Royal Liverpool University Hospital

Professor Dame Carol Robinson OBEProfessor of Chemistry, University of Oxford

Professor Chas BountraChief Scientist (SGC), Professor of Translational Medicine,University of Oxford

Chas is Professor of Translational Medicine in the Nuffield Department of Clinical Medicine and Associate Member of the Department of Pharmacology at the University of Oxford. He is also a Visiting Professor in Neuroscience and Mental Health at Imperial College, London. Chas is an invited expert on several government and charitable research funding bodies, and an advisor for many academic, biotech

and pharma drug discovery programmes.

Our Scientific Committee

Assay Development, Screening & Emerging Technologies

Innovations In Chemistry

Target Identification & Validation

Oncology & Immunology

Innovations In Predictive & Translational Models

Coming Closer To The Patient – Cells & Genes In Therapy & Diagnostics

Katy KettleboroughMRCT Centre for

Therapeutics DiscoveryStevenage Bioscience Catalyst

Michael DabrowskiPelago Bioscience AB

Edward TateImperial College London

Simon WardUniversity of Sussex

Véronique BiraultThe Francis Crick Institute

Malcolm HaddrickAstraZeneca

David GilhamInstitute of Cancer Sciences

Namir HassanImmunocore Ltd

Patrick EyersUniversity of Liverpool

Chris LarminieGlaxoSmithKline

Oliver WehmeieracCELLerate GmbH

Stephen WardCell & Gene Therapy Catapult

Programme at a glance

Session Summary

Towards the end of the 19th century, evidence had emerged pointing to the role of the immune system in combating cancers. Coleys toxin carried the tentative promise of long term anti-tumor responses through stimulating the immune system. During the 20th century, key advances were made in the discovery and characterisation of cellular and molecular players involved in immune recognition of cancer cells. These discoveries led to the recent wave of immunotherapeutic agents, T cell checkpoint blockers, with demonstrable durable anti-tumor activity, initially in melanoma, and expanding to other indications. There are now a plethora of immunotherapeutic modalities in clinical development; these are being tested as single agents and in combination. This track will review the various modalities showing promise, including protein based biologics and cell therapies, as well as surveying the tumor landscape for opportunities to disrupt the tumor micro environment.

THURSDAY 13TH OCTOBER: HALL 1B

Oncology & Immunology

#ELRIGDD16

Publication date 29/09/2016. More detail, abstracts, speaker biogs, etc, are available on our website www.elrig.org or our mobile app ‘ELRIG’.

Snapshots sponsored by:

In association with:

9:30 - 9:45

8:45 - 9:30

10:30 - 11:00

9:45 - 10:30

11:00 - 11:30

11:30 - 12:00

12:30 - 13:00

12:00 - 12:30

13:00 - 14:30

14:30 - 15:15

15:15 - 15:45

16:15 - 16:45

15:45 - 16:15

Introduction and Welcome

David KrigeImmunoCore

POSTER TASTERS

SNAPSHOT PRESENTATIONS - Essen Bioscience ltd, Promega UK Ltd, IntelliCyt Corporation, Tecan

DRAGON’S DEN/NETWORKING/DRINKS RECEPTION

LUNCH - EXHIBITION - POSTERS

TIME SPEAKER TITLE

Biomarker Strategy to Guide Clinical Development of ImmTAC's, a Novel Class of Biologic Drugs Based on Proprietary T cell receptor (TCR) Technology

Drug Safety in Drug Development

Analysis of Reciprocal Tumour-Stroma Signalling by Cell-Specific Phosphoproteomics

Immuno-oncology: harnessing the immune system to combat cancer

Martin PuleUCL

COFFEE BREAK

Claus JorgensenCancer Research UK Manchester Institute

Thierry WurchServier

POSTER SESSION

Session Chairs

Caroline DiveManchester University

CHAIRS: Namir Hassan, Immunocore and David Gilham, Manchester Cancer Research Centre

16:45 - 17:4517:00 - 19:00

Robert WilkinsonMedimmune

New Patient Relevant Models to Evaluate Much Needed Therapeutics for Small Cell Lung Cancer

Immunotherapy in the 21st Century: A Game Changing Paradigm in Oncology

PLENARY KEYNOTE: ROOM 3Professor Munir PirmohamedDavid Weatherall Chair in Medicine, Royal Liverpool University Hospital

PLENARY KEYNOTE: ROOM 3Professor Chas BountraOxford SGC - University of Oxford

“How can we build a new drug discovery ecosystem,which will complement Boston?”

TBA

10TH ANNIVERSARY GALA CELEBRATION AT THE MUSEUM OF LIVERPOOL18:30 - 21:00

Session Summary

The high rate of failure of drug discovery due to lack of efficacy or undesirable safety, demands the development of improved screening assays and translational models. In both instances, increasing the ‘predictive power’ of these approaches may lead to more effective delivery of medicines to patients. This session will focus on innovative approaches to increase the biological value of plate based screens and translational models aiming to drive the success of drug discovery efforts.

THURSDAY 13TH OCTOBER: HALL 1C

Innovations in Predictive & Translational Models

#ELRIGDD16


Snapshot sponsored by: Takara Bio

9:30 - 9:45

8:45 - 9:30

10:30 - 11:00

9:45 - 10:30

11:00 - 11:3011:30 - 12:00

12:30 - 13:00

12:00 - 12:30

13:00 - 14:30

14:30 - 15:15

15:15 - 15:45

16:15 - 16:45

15:45 - 16:15


Uwe MarxTissUse

POSTER TASTERS

SNAPSHOT: Sponsored by Takara Bio EuropeProfessor Geny Groothius presents: Precision-cut tissue slices as translational and predictive ex vivo model for ADME and toxicity.

NETWORKING/DRINKS RECEPTION


TIME SPEAKER TITLE

Chip-Based Microphysiological Systems and Drug Discovery


High-Efficiency Cellular Reprogramming with Microfluidics for Patient-Specific Disease Modelling

Small Cell Lung Cancer Circulating Tumour Cell-Derived Explants - A New Preclinical Platform for Examining Drug Response

Kris FreseManchester University

COFFEE BREAKConfocal High Content Screening of Cardiac and Liver Microtissues for the Improved Prediction of Drug Induced Toxicity

Nicola ElvassoreUCL

Vivian LiThe Francis Crick Institute

POSTER SESSION

Session Chairs

Ellinor HornbergAstraZeneca

CHAIRS: Malcolm Haddrick, AstraZeneca and Veronique Birault, Crick Institute

16:45 - 17:4517:00 - 19:00

Paul WalkerCyprotex

Application of an In vitro Human Airway Epithelial 3D Model for the Detection of Lung Irritancy Following Drug Treatment

Intestinal organoids: disease modelling and regenerative medicine





Innovations in Chemistry

Session Summary #ELRIGDD16

THURSDAY 13TH OCTOBER: ROOM 3

Advances in medicinal chemistry and chemical biology continue to drive innovation in drug discov-ery, unlocking new modes of action and the potential to address ‘undruggable’ targets. This session will focus on the increasingly recognised ability of small molecules to rewire biomolecular interactions through exploitation of unconventional binding modes, and remarkable recent progress in manipulating key pathways through multi-protein and nucleic acid complexes. Case studies range from cutting edge and disruptive concepts, through to novel approaches that have delivered candidates to the clinic.



9:30 - 9:45

8:45 - 9:30

10:30 - 11:00

9:45 - 10:30

11:00 - 11:30

11:30 - 12:00

12:30 - 13:00

12:00 - 12:30

13:00 - 14:30

14:30 - 15:15

15:15 - 15:45

16:15 - 16:45

15:45 - 16:15


Stephan Seiber=TU Munich

POSTER TASTERS

SNAPSHOT PRESENTATIONS - Dundee University Drug Discovery Unit, TTP Labtech, Gilson

DRAGON’S DEN/NETWORKING/DRINKS RECEPTION


TIME SPEAKER TITLE

Chemical Tools to Manipulate Bacterial Virulence


Beyond Small Molecule Inhibition: New PossibilitiesThrough Induced Intracellular Protein Degradation

COFFEE BREAK

Specific Correction of Alternative Survival Motor Neuron 2 (SMN2) Splicing by Small Molecules: Discovery of a Potential Novel Medicine to Treat Spinal Muscular Atrophy

John HarlingGlaxoSmithKline

POSTER SESSION

Session Chairs

Andy MerrittMRC Technology

CHAIRS: Simon Ward, University of Sussex Ed Tate, Imperial College London

16:45 - 17:4517:00 - 19:00

Hasane RatniRoche

From Fragment Hits to Selective Nanomolar Inhibitors of Human PAICS Without X-ray




Small-Molecule Stabilization of 14-3-3 PPls: Possible New Approaches in Cancer, Cystic Fibrosis and Parkinson's Disease.

Christian OttmanEindhoven

Ben DavisOxford University

Sugars and Proteins


Coming Closer to the Patient – Cells & Genes in Therapy and DiagnosticsFRIDAY 14TH OCTOBER: HALL 1B


As the Cell and Gene therapy field progresses from R&D to commercial reality, the focus increases on manufacturing challenges including scale up and rapid analytics. Our speakers will present how they are using the best of the Biologics technologies with innovative approaches to drive increased process reliability and reduce the cost of goods. Critical to this is the understanding of the efficacy of highly complex therapeutic products. Cell-based assays are in demand to monitor the efficacy of a gene, protein or cell therapy as a companion diagnostic or tool for quality control in batch release testing. We’ll hear how the sustained reproducibility required for GMP assays can be achieved even with a fickle player like a cell.



9:00 - 9:15

10:00 - 10:30

9:15 - 10:00

10:30 - 11:00

11:00 - 11:30

12:00 - 12:30

11:30 - 12:00

12:30 - 14:00

14:00 - 14:45

14:45 - 15:15

15:45 - 16:15

15:15 - 15:45


POSTER TASTERS

SNAPSHOT PRESENTATIONS - Caltag-Medsystems Ltd, Evercyte GmbH, DiscoverX,Cellular Dynamics, Sygnature Discovery

CLOSE OF CONFERENCE REMARKS - WITH PRIZE DRAW - ROOM 3


TIME SPEAKER TITLE

Mass Spectrometry and its Role in Membrane ProteinDrug Discovery

Point of Care Thawing of Cryopreserved Cell Therapies

Synthetic Promoters: Precision in Gene Control Michael RobertsSynpromics

COFFEE BREAK

Cell Therapy for Diabetes

Stuart MilneAsymptote

Gergely ToldiSemmelweis University

COFFEE BREAK

Session Chairs

Ludwig DemlLophius Bioscience

CHAIRS: Oliver Wehmeier, Accelerate, Stephen Ward and Julie Kerby, Cell & Gene Therapy Catapult

16:15 - 16:45

16:45 - 17:15

Kevin DochertyUniversity of Aberdeen

Novel T-cell-based tools in diagnosis and management of microbial infections

Detection of Multidrug Resistance Activity Using Flow Cytometry as a Diagnostic Tool

PLENARY KEYNOTE: ROOM 3Professor Carol RobinsonProfessor of Chemistry, University of Oxford

Bo KaraGlaxoSmithKline

Commercialisation of ex-vivo cell gene therapy products: Establishing processes, manufacturing and supply chains”

Target Identification & Validation


FRIDAY 14TH OCTOBER: HALL 1C

We have entered into a new era for target identification and validation, where genomics and proteomics are meeting head-on to reveal the complexity of life. Next generation sequencing technologies have enabled a wealth of functional genomics studies such as ENCODE and BLUEPRINT. Reinterpretation of genetics data generated over the last decade is starting to identify many new targets at both general and individual therapeutic levels, and an explosion in transcriptomic and proteomic information has created a wealth of additional information. In parallel, our ability to build more complex in-vitro and ex-vivo cell/tissue systems is enabling us to explore and validate these targets in systems that are ever-more representative of (patho) physiological niches where they operate.

Critically, the development of CRISPR and TALENs technologies promises the ability to edit target genes for precise ‘gold-standard’ chemical biology target validation at scale and across species, from bacteria to humans. These complex (and costly) technologies are generating new types and scales of data, which will have the effect of creating more and more target identification and validation work. To support this need, new working models are being developed, with industry and academia working together in this pre-competitive space.



9:00 - 9:15

10:00 - 10:30

9:15 - 10:00

10:30 - 11:00

11:00 - 11:30

12:00 - 12:30

11:30 - 12:00

12:30 - 14:00

14:00 - 14:45

14:45 - 15:15

15:45 - 16:15

15:15 - 15:45


Alessio CiulliUniversity of Dundee

POSTER TASTERS

SNAPSHOT PRESENTATIONS - INTEGRA Biosciences Ltd, Horizon, ReproCELL, Pelago Bioscience, NanoTemper Technologies Ltd, Insphero



TIME SPEAKER TITLE

On-Target Validation of Chemical Probes:Bump-and-Hole and PROTACs

Mass Spectrometry and its Role in Membrane Protein Drug Discovery

Chemical Proteomics as a Tool for Target Identification and Validation

From Artemisinin to a Tetraoxane-Based Antimalarial Drug Candidate

Paul O'NeillUniversity of Liverpool

COFFEE BREAK

Integrated Genomic and Genetic Approaches to Drive COPD Target Discovery

Ed TateImperial College London

Jon MooreHorizon Discovery

COFFEE BREAK

Session Chairs

Luke O'NeillTrinity College Dublin

CHAIRS: Chris Larminie, GlaxoSmithKline and Patrick Eyers, University of Liverpool

16:15 - 16:45

16:45 - 17:15

David MichalovichGlaxoSmithKline

Metabolic Reprogramming in Macrophages During Inflammation: Prospects for New Therapeutics

Can Genome Editing Find Novel Synthetic Lethal Targets for Cancer Therapy


Assay Development & Screening


FRIDAY 14TH OCTOBER: ROOM 3

In Drug Discovery there is an ever-increasing emphasis on the ability to identify high quality hits. This has resulted in the search for new assays and screening paradigms. Technologies already established later in the discovery cascade, such as CETSA and Mass Spec are being applied in earlier in the value chain to deliver new chemical starting points, and the resurgence of interest in phenotypic screening is starting to deliver in terms of hits and novel targets. This session will explore innovative approaches with established and novel platforms using case studies to demonstrate successful applications.



9:00 - 9:15

10:00 - 10:30

9:15 - 10:00

10:30 - 11:00

11:00 - 11:30

12:00 - 12:30

11:30 - 12:00

12:30 - 14:00

14:00 - 14:45

14:45 - 15:15

15:45 - 16:15

15:15 - 15:45


Thomas Lundb ckKarolinska Institutet

POSTER TASTERS

SNAPSHOT PRESENTATIONS - Genedata AG, BioTek Instruments, Sartorius Stedim Biotech,Corning Life Sciences, BMG Labtech, SAL Scientific Limited



TIME SPEAKER TITLE

Microplate-Based Measurements of Target Engagement in Live Cells With the Cellular Thermal Shift Assay – a Reflection on Screen Results and Quantitative Interpretations

Mass Spectrometry and its Role in Membrane Protein Drug Discovery

Phenotypic Screening to identify inhibitors of the Wnt Pathway

Proteome Wide CETSA as a New Biophysics Strategy To Map Target Engagement and the Global Cellular Responses to Drugs

P r NordlandKarolinska Institutet

COFFEE BREAK

Rethinking Cell Line Development from Selection to Single Clone

Mark StubbsThe Institute of Cancer Research (ICR)

Jonathan WingfieldAstraZeneca

COFFEE BREAK

Session Chairs

David BrierleyGlaxoSmithKline

CHAIRS: Michael Dabrowski, Pelago Bioscience and Katy Kettleborough, MRCT

16:15 - 16:45

16:45 - 17:15

Keith BreinlingerBerkeley Lights

Identifying Small Molecule Agonists of Macrophage Phagocytosis Using a High Content Phenotypic Imaging Based Approach

Assay Development and Delivery of a High Throughput Screen to Identify Inhibitors of Glutathione-Disulfide Reductase: Application of Acoustic Mass Spectrometry


Genedata WorkshopTHURSDAY 13TH OCTOBER: ROOM 11A

Today, screening, imaging and genomics are the main sources of experimental data in drug discovery, boosted by standardization, laboratory automation and falling cost per data point. Analyzing and interpreting screening data in discovery projects remains challenging, however, for three reasons:

• New in-vitro assay systems tuned for physiological relevance tend to be more complex and yield more complex data as well

• New detection technologies and modalities provide richer information, sometimes down to the single cell / molecular level

• Drug discovery projects require tighter-knit collaboration on screening data and results, in short cycles.

This is becoming an even greater challenge with the collaborative R&D outsourcing. Thus, screening scientists need to handle daily the biological, technical and collaborative complexity of experimental data. We will discuss in this workshop how this can be done efficiently: Adopting a harmonized best-practice approach to analysis for generating interpretable results; extending it with assay- and technology-specific procedures as needed; managing data and results on a collaborative platform for secure sharing, access, and full use of that information in discovery projects.

The workshop will consist of a series of presentations and discussions outlining modern standard approaches to analysis and management of screening data, e.g.:

• A collaborative platform for managing experimental results from all in-vitro assays• Integrating complementary information from multiple screening technologies for hit qualification,

lead optimization, profiling and safety.• From biophysical screens to molecular binding parameters• Phenotypic high content assays and their analysis• Combination screens for oncology: simplifying synergy

This workshop is for screening scientists who want to advance their knowledge of analysis procedures, find ways to more efficiently analyze their data and understand approaches to data and result sharing.


9:30 - 9:40

10:00 - 10:30

9:40 - 10:00

11:00 - 11:30

Welcome and Introduction

Dave Murray, AstraZeneca

TIME PRESENTER TRACK

Integrating screening data across a large multisite pharma organization

A foundation in the murky waters of Discovery: Laying a platform across piles of in-vitro screens

Margarita Shatalina, Genedata

COFFEE BREAK

Stephan Heyse, Genedata

10:30 - 11:00 Emilie Bureau, MRCT Phenotypic high-content screen measuring aggregate clearance in neurodegenerative diseases

12:00 - 12:30

11:30 - 12:00

Michelle Newman, MRCT Drug combinations as potential oncology therapeutics: Data analysis with Genedata Screener

High-content screening: How to easily select meaningful feature combinations

Lope Florez, Genedata

12:30 - 13:00 John Vincent, AstraZeneca Simplifying synergy: Combination screens

Labcyte WorkshopTHURSDAY 13TH OCTOBER: ROOM 11C

Labcyte are excited to be presenting a great line-up of speakers and sessions at ELRIG Drug Discov-ery 2016, in Liverpool, UK. Their seminar highlighting the Echo acoustic liquid dispensing technology and how it’s impacting personalised medicine and drug discovery, will feature speakers from Uppsala University, Institute for Molecular Medicine Finland, and AstraZeneca. Be sure to stop by the Labcyte Stand E2 to learn more about their groundbreaking technology and how it can enable your science and research.


9:30 - 9:45

10:20 - 10:50

9:45 - 10:15

10:50 - 11:30

11:30 - 11:40

11:40 - 12:10

Introduction to TRACK 1

Krister WennerbergFIMM-EMBL Group Leader, Institute of Molecular Medicine Finland

Clive GreenGlobal Compound Manager, AstraZeneca

TIME PRESENTER TRACK

Targeting Individual Cancers Using Chemical Systems Medicine

Automated Acoustic Dispensing; Clinic and Research

Kristin BlomBiomedical Scientist, Ph.D.-Student Uppsala University Hospital, Uppsala, Sweden

COFFEE BREAK

Introduction to TRACK 2

Labcyte

TRACK 1: PERSONALISED HEALTH AND IMPACT OF ACOUSTIC DISPENSING

Labcyte TRACK 2: FUTURE IMPACT OF ACOUSTIC DISPENSING IN DRUG DISCOVERY PROCESSES

From Routine to Extreme Cherry Picking. Design of New Acoustically Compatible Storage Tubes for Liquid Samples

12:15- 12:45 Ian SinclairAssociate Principal Scientist, AstraZeneca

Echo-MS A Versatile Platform for Ultrafast Mass Spectrometry Analysis in Drug Discovery

Aidpath WorkshopFRIDAY 14TH OCTOBER: ROOM 11A


Despite the accelerating advances and vast investment in technologies and molecular understanding in biology & diseases, success in medical research finding new drug entities remain stagnated since 1980s. The continuous high attrition in drug discovery and worsening unmet medical needs demand significant improvement in efficacy translation and safety prediction from in vitro pre-clinical drug discovery to disease diagnosis and patient care.

This workshop will complement the main conference to provide technically-oriented and interactive awareness sessions on emerging biological and translational platforms which enhance the physiological relevancy and predictivity of target biological/disease models. These advances will all contribute to accelerate holistic drug discovery approaches and new clinical practice which will translate to better drug and treatment for the patients.

9:10 - 9:20

10:30 - 11:00

Workshop Introduction - In vitro to Clinic

TIME PRESENTER TITLE

COFFEE BREAK

Eric TangPhoenix Biomedical

9:20 - 9:30 AIDPATH IntroductionGloria BuenoUniversidad de Castilla-La Mancha

9:30 - 10:00 Organoid ModelsFarzin PourfazadHubrecht Organoid Technology, HUB

10:00 - 10:30 3D models/PDX in DD/PMAnna GrabowskaUniversity of Nottingham

11:00 - 11:30 Microfluidic - therapyCharlotte DyerUniversity of Hull

11:30 - 12:00 Safety/Tox modelsTBC

12:00 - 12:30 HistopathologyRupert EckerTissueGnostics GmbH

14:00 - 14:35 3D/Organotypic culture models Eric TangPhoenix Biomedical

14:35 - 15:10 Microfluidic devicesTudor PetreusOncology iMed, AstraZeneca

15:10 - 15:45 3D imaging/LightsheetGopi ShahCancer Institute, Cambridge

12:30 - 14:00 LUNCH

15:45 - 16:15 COFFEE BREAK

16:45 - 17:15 CLOSE OF CONFERENCE WITH PRIZE DRAW

16:15 - 16:45 CM - Path InitiativeSarah CouplandUniversity of Liverpool

Come and listen to some of our contestants ‘pitch’ their businesses and products to a panel of ‘Dragons’ - all established entrepreneurs within our industry.

The aim of this contest is to promote innovation - no real money or investment is on offer, but it is is a great chance to hear about some of our new businesses and see them reviewed and ‘critiqued’ by a panel of experts - and you never know where it might lead.

Dragon’s Den will take place in the exhibition hall after the poster session, during the drinks reception on Thursday 13th October. This will be followed by the Drug Discovery 10th anniversary celebration event at the Museum of Liverpool.

Dragon’s Den

This year, ELRIG celebrates the 10th anniversary of our flagship event, Drug Discovery. To mark the occasion we are hosting a gala celebration evening at the Museum of Liverpool and we would like you to be a part of it.

This informal event is the perfect way to network with colleagues, industry peers and vendors in an informal setting. There will be welcome drinks, canapés and live music from ‘Made in Liverpool’ all against the backdrop of the People’s Republic Gallery which boasts ‘Britain’s best Window with a View’.

6:30 - Welcome drinks and canapés9:00 - Close of event

All registered delegates who attend Drug Discovery 2016 are invited. Simply bring your registration badge with you on the evening. We look forward to seeing you there.

You are invited to the Drug Discovery10th Anniversary Gala CelebrationTHURSDAY 13TH OCTOBER: MUSEUM OF LIVERPOOL

Sponsored by:

© Ant Clausen

Poster Competition

WI-FI and the ELRIG Mobile App

Every year at ELRIG Drug Discovery we get a fantastic range of Posters presented. We invite YOU, the delegates, to vote for what you think is the best poster.

Simply fill in your choice on the voting form in your programme and return it to the ELRIG registration desk.

The winner will be announced in the closing address (Room 3 - 16:45 on Friday 14th October). Votes returned by 3pm on Friday 14th will be entered into a PRIZE DRAW – also made at the closing address. (Please note you need to be there in person to win).

www.elrig.org

THE ELRIG TECHNOLOGY PRIZE

Please vote for what you think is the most interesting / innovative technology you have seen at the exhibition.

Company:

Technology:

THE ELRIG POSTER PRIZE

Please vote for what you think is the most interesting poster you have seen at this event.

Poster Number:

VOTING

All votes will be entered into a prize draw for a Kindle at the closing session

Name:

Company:

Mobile No:

E-mail:

Please return forms to the ELRIG desk byAFTERNOON COFFEE BREAK on Day 2 - Thank you!

Please give us your contact details, so we can find you if you win!

Please have a good look around the exhibition: it’s the exhibitors’ support that keeps ELRIG events free to attend. We invite YOU, the delegates, to vote for what you think is the best technology being shown in the exhibition.

Fill in your choice on the voting form in your programme and return it to the ELRIG registration desk. The winner will be announced in the closing address (Room 3 - 16:45 on Friday 14th October). Votes returned by 3pm on Friday 14th will be entered into a PRIZE DRAW – also made at the closing address. (Again please note that you need to be there to win).

Technology Prize

Download the free ELRIG app and access all our conference information, programme and more from your phone or tablet.

• view the event programme, presentation and poster abstracts and speaker profiles• view exhibitor video presentations• view the exhibitor guide• view the delegate and exhibitor list• organise your day with your own favourites list• share your profile as vCard and QR Code and scan exhibitor QR code information tags.• network – contact delegates, other exhibitors and speakers easily through opt-in

directories and integration with Linked-In, Twitter and Facebook

WI-FI at ACC, Liverpool is free. Simply select the network FREE_WIFI to be connected. There is no username or password.

To download the ELRIG app, visit the app store appropriate to your tablet or smart phone, scan the QR code or visit the ELRIG website: www.elrig.org/mobile-app/

WI-FI Sponsored by:

Drug Discovery 2016 Exhibitors

4titude Ltdwww.4ti.co.uk

Agilent Technologieswww.agilent.com

AMS Biotechnology (Europe) Ltdwww.amsbio.com

AstraZeneca UKwww.astrazeneca.co.uk

Avacta Life Scienceswww.avactalifesciences.com

Axol Bioscience Ltdwww.axolbio.com

Bigneatwww.bigneat.co.uk

BioTek Instrumentswww.biotek.com

BlueCatBio GmbHwww.bluecatbio.com

Bruker Daltonicswww.bruker.com

Caltag Medsystems Ltdwww.caltagmedsystems.co.uk

Cambridge Biosciencewww.bioscience.co.uk

Cambridge Research Biochemicalswww.crbdiscovery.com

Cellular Dynamics Internationalwww.cellulardynamics.com

Cisbio Bioassayswww.cisbio.com

Corning Life Scienceswww.corning.com/lifesciences

DiscoverXwww.discoverx.com

Dundee University Drug Discovery Unitwww.drugdiscovery.dundee.ac.uk

Genedata AGwww.genedata.com

Gilson Scientific ltdwww.gilsonuk.com

Greiner Bio Onewww.gbo.com

Hamamatsu Photonics UK Ltd www.hamamatsu.com

Horizon Discoverywww.horizondiscovery.com

Image Solutions (UK) Ltdwww.imsol.co.uk

Innoprotwww.innoprot.com

KBiosystems Limitedwww.kbiosystems.com

Labcyte Incwww.labcyte.com

LabLogic Systems Ltdwww.lablogic.com

LGC - ATCCwww.lgcstandards-atcc.org

Liconic UK Ltdwww.liconic.com

Mathisen & Macara LLPwww.mathisen.co.uk

Miltenyi Biotec GmbHwww.miltenyibiotec.com

Pelago Bioscience ABwww.pelagobio.com

PerkinElmerwww.perkinelmer.com/lifesciences

Porvair Sciences Ltdwww.porvair-sciences.com

ReproCELLwww.reprocell.com

SAL Scientific Ltdwww.salscientific.com

Sekisui XenoTechwww.xenotech.com

Sygnature Discoverywww.sygnaturediscovery.com

Titian Software Ltdwww.titian.co.uk

TTP Labtechwww.ttplabtech.com

UPM-Kymmene Corporationwww.upm.com

Venomtech Ltdwww.venomtech.co.uk

Wildcat Laboratory Solutionswww.wildcatlaboratorysolutions.com

Zinsser Analytic GmbHwww.zinsser-analytic.com

Promega UK Ltdwww.promega.com

Essen BioSciencewww.essenbio.com

Eventflowww.myeventflo.com

Evercyte GmbHwww.evercyte.com

Festo Ltdwww.festo.co.uk

Formulatrix, Inc.www.formulatrix.com

Molecular Devices (UK) Ltdwww.moleculardevices.com

Moor Instruments Ltdwww.moor.co.uk

NanoTemper Technologies Ltdwww.nanotemper-technologies.com

Nemaura Pharma Ltdwww.nemaura.co.uk

Nexcelom Bioscience Ltdwww.nexcelom.co.uk

Peak Analysis and Automation (PAA)www.paa-automation.com

Langton Howarthwww.langtonhowarth.co.uk

Event Platinum Sponsors

Event Gold Sponsors

IntelliCyt Corporationwww.intellicyt.com

Pall ForteBio LLCwww.fortebio.com

Event Silver Sponsors

Event Media Partners

Innovation Zone

Beckman Coulter Life Sciencewww.beckman.com

HighRes Biosolutions Ltdwww.highresbio.com

Takara Bio Europewww.clontech.com

BMG LABTECH Ltdwww.bmglabtech.com

Hamilton Sales & Service UK Ltdwww.hamiltonrobotics.com

INTEGRA Bioscience Ltdwww.integra-bioscienes.com

Sartorius Stedim Biotechwww.tapbiosystems.com

Tecan UK Ltdwww.tecan.com

acCELLerate GmbHwww.accellerate.me

Apley Technology Ltdwww.apleytechnology.co.uk

Ascellnawww.ascellna.com

BioFluidix GmbHwww.biofluidix.com

CryoXtract Instrumentswww.cryoxtract.com

HCS Pharmawww.hcs-pharma.com

Microlab Technologies Ltdwww.microlabtech.co.uk

MIP Diagnostics Limitedwww.mip-dx.com

Peak Proteins Ltdwww.peakproteins.com

Pepscopewww.pepscope.com

Scitegrity Limitedwww.scitegrity.com

Williamson Biotech Solutions ltdwww.williamsonbiotechsolutions.com

CELENYSwww.celenys.com

Swift Analyticalwww.swiftanalytical.com

Simomicswww.simomics.com

BioNowwww.bionow.co.uk

DDNewswww.ddn-news.com

DDWwww.ddw-online.com

Drug Target Reviewwww.drugtargetreview.com

MedChemNetwww.medchemnet.com

N8 Partnershipwww.n8research.org.uk

Technology Networkswww.technologynetworks.com

UKSPAwww.scienceparks.co.uk

British Pharmacological Societywww.bps.ac.uk

UK Pharmacogenetics & Stratified Medicine Networkwww.uk-pgx-stratmed.co.uk

Zyme Communicationswww.zymecommunications.com

Select Sciencewww.selectscience.net

Future ELRIG Meetings

Make sure you are part of these events. Book your place NOW!For more information please contact the ELRIG team:

Email: [email protected] Tel: +44 (0)1904 405 177

www.elrig.org

Pharmaceutical Flow Cytometry & Imaging22nd – 23rd November 2016

GlaxoSmithKline Stevenage, UK

Research & Innovation March 29th and 30th 2017

Homerton CollegeCambridge, UK

Advances in Cell Based Screeningin Drug Discovery

10th - 11th May 2017 AstraZeneca

Gothenburg, Sweden

Drug Discovery 2017Oct 3rd & 4th 2017

ACC LiverpoolLiverpool, UK

www.twitter.com/@elrig_uk

www.facebook.com/ELRIGUK/

www.linkedin.com/company/elrig

WI-FI at ACC, Liverpool is free. Simply select the network FREE_WIFI to be connected.

There is no username of password.

Documents

· 2016-10-06 · Welcome to Drug Discovery 2016 As Scientific Program chairs it is our great pleasure to welcome you to Liverpool and the 10th Annual ELRIG Drug Discovery event. Through